WallStreetZenWallStreetZen

NASDAQ: EXAI
Exscientia PLC Stock Forecast, Predictions & Price Target

Analyst price target for EXAI

Based on 3 analysts offering 12 month price targets for Exscientia PLC.
Min Forecast
$7.00+7.36%
Avg Forecast
$8.67+32.93%
Max Forecast
$10.00+53.37%

Should I buy or sell EXAI stock?

Based on 3 analysts offering ratings for Exscientia PLC.
Buy
Strong Buy
1 analysts 33.33%
Buy
0 analysts 0%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EXAI stock forecasts and price targets.

EXAI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-01-05
lockedlocked$00.00+00.00%2023-10-17
lockedlocked$00.00+00.00%2023-10-11

1 of 1

Forecast return on equity

Is EXAI forecast to generate an efficient return?
Company
N/A
Industry
18.39%
Market
28.92%

Forecast return on assets

Is EXAI forecast to generate an efficient return on assets?
Company
N/A
Industry
9.3%

EXAI revenue forecast

What is EXAI's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$51.4M+74.29%
Avg 2 year Forecast
$72.9M+147.26%
EXAI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EXAI revenue growth forecast

How is EXAI forecast to perform vs Biotechnology companies and vs the US market?
Company
72.19%
Industry
1,290.61%
Market
37.91%
EXAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EXAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EXAI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EXAI$6.52$8.67+32.93%Buy
OLMA$14.80$22.00+48.65%Strong Buy
YMAB$18.69$21.00+12.36%Buy
ORIC$14.66$17.50+19.37%Buy
ALLO$4.94$8.33+68.68%Strong Buy

Exscientia Stock Forecast FAQ

Is Exscientia Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: EXAI) stock is to Buy EXAI stock.

Out of 3 analysts, 1 (33.33%) are recommending EXAI as a Strong Buy, 0 (0%) are recommending EXAI as a Buy, 2 (66.67%) are recommending EXAI as a Hold, 0 (0%) are recommending EXAI as a Sell, and 0 (0%) are recommending EXAI as a Strong Sell.

If you're new to stock investing, here's how to buy Exscientia stock.

What is EXAI's revenue growth forecast for 2024-2025?

(NASDAQ: EXAI) Exscientia's forecast annual revenue growth rate of 72.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 1,290.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 37.91%.

Exscientia's revenue in 2024 is $29,831,707.On average, 1 Wall Street analysts forecast EXAI's revenue for 2024 to be $6,395,657,298, with the lowest EXAI revenue forecast at $6,395,657,298, and the highest EXAI revenue forecast at $6,395,657,298.

In 2025, EXAI is forecast to generate $9,073,401,445 in revenue, with the lowest revenue forecast at $9,073,401,445 and the highest revenue forecast at $9,073,401,445.

What is EXAI's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: EXAI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 9.3%.

What is EXAI's Price Target?

According to 3 Wall Street analysts that have issued a 1 year EXAI price target, the average EXAI price target is $8.67, with the highest EXAI stock price forecast at $10.00 and the lowest EXAI stock price forecast at $7.00.

On average, Wall Street analysts predict that Exscientia's share price could reach $8.67 by Jan 5, 2025. The average Exscientia stock price prediction forecasts a potential upside of 32.93% from the current EXAI share price of $6.52.

What is EXAI's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: EXAI) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.